What's new? Log in Free sign up

Medicenna Therapeutics (MDNAF)

Company Profile

Company profile

Ticker

MDNAF, MDNA

Exchange

Website

Incorporated

Canada (Federal)

Location

Ontario, Canada

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Mississippi Power • Alabama Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

MDNAF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

$14.59 mm in equity / options / securities to be acquired, sold $14.55 mm, 1 investor

Notice of effectiveness

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

Prospectus update (post-effective amendment)

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Withdrawal of amendment

Registration of securities for employees (post-effective amendment)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

RA CAPITAL MANAGEMENT, L.P.

Financial summary

Financial statements Chart MDNAF financial data

Quarter (USD)	Mar 23	Mar 22	Mar 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 23	Mar 22	Mar 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q2 2024

MDNAF institutional ownership history Ownership history

12.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	2	–
Opened positions	0	0
Closed positions	0	1	EXIT
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	9.85 mm	9.85 mm	–
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Merchant Fahar	5.50 mm	$0.00	0.0%
Hirschman Orin	4.35 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
Hirschman Orin	4.35 mm	0.00	0.0%
Merchant Fahar	5.50 mm	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Press releases

From Benzinga Pro

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQX:MDNAF), a clinical-stage immunotherapy company focused on the development of

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.